VA Seeks to Reduce Use of Popular but Much-overused Class of Drugs

When you experience a relentless bout of heartburn or acid reflux, reaching for a common, over-the-counter stomach medication feels like a no-brainer. For millions of people, these drugs—known as Proton Pump Inhibitors (PPIs)—are a standard fixture in the daily routine. In fact, within the U.S. Department of Veterans Affairs (VA) health system alone, roughly one in six Veterans relies on them.

But a major initiative from the VA is highlighting a growing concern in modern medicine: we might be drastically overusing them.

While PPIs are highly effective when taken properly for short-term relief, data suggests that up to 60% of PPI prescriptions lack a clear, evidence-based reason for use. Because these medications are often inexpensive and widely available, patients frequently stay on them for years without a second thought. However, long-term chronic use has been linked in observational studies to a variety of serious health risks, including bone fractures, pneumonia, magnesium deficiencies, and severe gut infections.

To tackle this issue head-on, the VA has launched a massive national de-prescribing effort called RaPPID (the National Randomized Proton Pump Inhibitor De-prescribing Program). Here are the key highlights of how this initiative is shifting the approach to veteran care:

• A Massive Scale: RaPPID is set to be one of the VA's largest medication safety efforts, aiming to engage up to 1 million Veterans across the country.

• Smart Tech for Smarter Care: Instead of leaving it up to chance, the program uses an intelligent algorithm to scan electronic health data. It automatically flags patients who are using PPIs for uncomplicated acid reflux and builds a dashboard for pharmacists and primary care teams to review safely.

• The Power of "De-prescribing": Rather than just cutting patients off, clinicians use the data to have informed conversations about safely tapering down the dosage, stopping the drug entirely if it's no longer needed, or switching to safer alternatives.

• A Blueprint for Low-Value Care: Beyond just stomach medicine, researchers are studying the RaPPID rollout to learn how health systems can successfully phase out other overutilized, low-value clinical practices in the future.

Ultimately, the goal isn't to demonize a helpful class of medication, but to ensure that patients are getting the right treatment, at the right dose, for the right amount of time.

Want to dive deeper into the data, the ongoing clinical trials, and the team of scientists leading this health care shift?

👉 Read the full article on the official VA Research website.

All content on this website is provided for informational and educational purposes only; it is not medical advice and does not establish a doctor–patient relationship. Always consult a licensed healthcare provider before making any health, diet,or supplement changes, especially if you are pregnant, nursing, taking medications, or have a medical condition. Statements about dietary supplements or other health products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.